Frontlight ResearchEarly access
Not yet recruitingPhase 3
Vitamin D supplements for heart scarring after acute myocarditis
Tests vitamin D for heart scarring in adults with acute myocarditis and low vitamin D.
Key facts
- Who runs it
- Spanish Society Of Cardiology
- Where
- Spain5 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Effect of Vitamin D on MyocardIal Fibrosis in Acute Myocarditis
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 152 people, planned
- Started
- 1 Jul 2026
- Expected to end
- 30 Jun 2028
- Type of study
- Interventional
- Record updated
- 10 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in hospital with acute myocarditis (inflammation of the heart muscle) and low vitamin D. It tests whether vitamin D supplements reduce heart muscle scarring.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Uncomplicated acute myocarditis confirmed by heart MRI (CMR), with scarring seen on the scan (LGE). Left ventricular ejection fraction (heart pumping strength) must be ≥40%.
- Earlier treatment
- People already taking vitamin D supplements cannot join.
- Biomarker or test result
- Blood 25OHD (vitamin D) level below 25 ng/mL.
Main reasons for not taking part
- Myocarditis with unstable blood pressure or circulation, sustained ventricular tachycardia or new heart conduction problems
- Myocarditis caused by immune checkpoint inhibitors, or eosinophilic or giant cell myocarditis
- Other heart muscle disease, congenital heart disease, or acute coronary syndrome or heart surgery in the last 3 months
- Pregnant or breastfeeding women, cancer or another life-threatening condition
- High calcium (>10.5 mg/dL), calcium kidney stones, or being unable to have heart MRI or gadolinium contrast
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Patients admitted with AM aged ≥18 years
- Diagnosis confirmed by CMR
- Left ventricular ejection fraction ≥40% on CMR
- Presence of LGE on CMR
- 25OHD levels <25 ng/mL
Who cannot take part
- Patients already receiving Vitamin D supplementation
- Immune checkpoint inhibitors-associated AM
- Known allergy or intolerance to calcifediol or its components
- Congenital heart disease
- Acute coronary syndrome (ACS) or cardiac surgery within the last 3 months
- Cancer or any other life-threatening condition
- Any contraindication to CMR procedures, including allergy or intolerance to gadolinium contrast media
- Any other medical or physical condition considered unappropriated by a study physician
- Granulomatous disorders (tuberculosis, sarcoidosis)
- Systemic Autoimmune Disorders
- Hypercalcemia (>10.5 mg/dL) or hypercalciuria
- Calcium nephrolithiasis
- Dilated, hypertrophic or arrhythmogenic cardiomyopathy
- Pregnant or lactating women
- Participation in other AM clinical trials
- Unable to provide written informed consent (either personally or through a designated legal representative) or to provide a contact telephone number
- AM complicated with hemodynamic instability, sustained ventricular tachycardia or new-onset conduction abnormalities
- Eosinophilic myocarditis
- Giant Cell myocarditis
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Evaluate the effect of Vitamin D supplementation on myocardial fibrosis at 6 months follow-up assessed by LGE CMR in patients with uncomplicated AM and low levels of 25OHD
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Effect of Vitamin D supplementation on MyocardIal Fibrosis in PaTients with Acute Myocarditis (EDIT-AM): a multicenter, open-label, randomized controlled trial
- Plain-language title
- Vitamin D supplements for heart scarring after acute myocarditisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 10 July 2026